Study on spesolimab for severe psoriasis flares withdrawn before starting
NCT ID NCT06886009
First seen Nov 01, 2025 · Last updated May 26, 2026 · Updated 24 times
Summary
This study was designed to track the safety and effectiveness of spesolimab in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The plan was to observe patients receiving the drug in routine medical practice, focusing on side effects and how well it cleared pustules. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ajou University Hospital
Suwon, 16499, South Korea
-
Asan Medical Center
Seoul, 05505, South Korea
-
Pusan National University Yangsan Hospital
Busan, 49241, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
Conditions
Explore the condition pages connected to this study.